接受5α-还原酶抑制剂男性的膀胱癌生存分析
该研究基于1997至2012年芬兰全国癌症登记中10,720例新诊断膀胱癌男性,随访中位4.17年,采用Cox回归分析5α-还原酶抑制剂与膀胱癌特异性死亡的关系。结果显示诊断前后使用5α-还原酶抑制剂均与膀胱癌死亡风险降低相关,而α受体阻滞剂无此关联。
要点
- 诊断前使用5α-还原酶抑制剂与膀胱癌死亡风险降低相关(HR 0.84)。
- 诊断后使用5α-还原酶抑制剂同样与死亡风险降低相关(HR 0.77)。
- α受体阻滞剂使用与膀胱癌生存无关联,提示结果非单纯适应证混杂。
核心结论
- 接受5α-还原酶抑制剂的膀胱癌患者疾病特异性生存优于未使用者,α受体阻滞剂则与生存无关,支持5α-还原酶抑制剂在膀胱癌中的获益。
研究设计与样本
- 基于芬兰全国癌症登记的人群队列,纳入1997至2012年新诊断膀胱癌男性10,720例,中位随访4.17年,采用校正年龄、性别、合并症、主要治疗及肿瘤范围的Cox回归分析。
主要发现
- 诊断前使用5α-还原酶抑制剂与膀胱癌死亡风险降低相关(HR 0.84,95%CI 0.73-0.97),且随使用年限延长风险下降更明显。
- 诊断前使用α受体阻滞剂与膀胱癌生存无关(HR 1.02,95%CI 0.91-1.13)。
- 诊断后使用5α-还原酶抑制剂与膀胱癌死亡风险降低相关(HR 0.77,95%CI 0.68-0.88)。
- 诊断后使用α受体阻滞剂与膀胱癌生存无关(HR 0.98,95%CI 0.90-1.07)。
- 5α-还原酶抑制剂带来的风险下降可持续至5年。
临床怎么用
- 在评估男性膀胱癌预后时,可将5α-还原酶抑制剂使用史作为潜在有利因素纳入考量。
- α受体阻滞剂使用史不改变对膀胱癌特异性生存的预期判断。
局限性
- 为观察性队列研究,可能存在残余混杂,原文以同期α受体阻滞剂使用评估适应证混杂但未报告其他未测混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Androgens may have a role in bladder carcinogenesis. We studied whether 5α-reductase inhibitors were associated with bladder cancer specific mortality in a population based cohort of men with bladder cancer. MATERIALS AND METHODS: The study cohort consisted of 10,720 Finnish men with bladder cancer newly diagnosed in 1997 to 2012 who were identified in a national cancer registry. Median followup was 4.17 years after bladder cancer diagnosis. We analyzed the HR and 95% CI of the risk of bladder cancer death by 5α-reductase inhibitor administration using Cox regression adjusted for age, gender, comorbidities, primary bladder cancer treatment and tumor extent at diagnosis. Lag time analyses were performed to assess the long-term risk association. Simultaneous administration α-blockers was considered to estimate possible confounding by indication. RESULTS: Administering 5α-reductase inhibitors before bladder cancer diagnosis was associated with a lower risk of bladder cancer death (HR 0.84, 95% CI 0.73-0.97). The risk decrease became stronger with years of use. Conversely prediagnostic administration of α-blockers was not associated with bladder cancer survival (HR 1.02, 95% CI 0.91-1.13). Similarly 5α-reductase inhibitor administration after diagnosis was associated with a decreased risk of bladder cancer death (HR 0.77, 95% CI 0.68-0.88). Bladder cancer survival was not associated with α-blockers (HR 0.98, 95% CI 0.90-1.07). The risk decrease due to 5α-reductase inhibitors persisted up to 5 years. CONCLUSIONS: Patients who receive 5α-reductase inhibitors have improved disease specific survival after bladder cancer diagnosis compared to those who do not receive them while α-blockers were not associated with survival. This supports the benefits of 5α-reductase inhibitors in bladder cancer.
引用
- Mäkelä VJ, Kotsar A, Tammela TLJ, et al. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors. J Urol. 2018. PMID: 29730200. doi:10.1016/j.juro.2018.04.082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。